Telix Pharmaceuticals (TLX) Current Assets (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Current Assets for 3 consecutive years, with $330.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Assets fell 45.02% year-over-year to $330.3 million; the TTM figure through Dec 2025 stood at $330.3 million (down 45.02% YoY), while the FY2025 annual figure was $330.3 million, down 42.07% from the prior year.
• Current Assets eased to $330.3 million in Q4 2025 per TLX's latest filing, from $600.7 million in the prior quarter.
• Across five years, Current Assets topped out at $600.7 million in Q4 2024 and bottomed at $151.4 million in Q4 2023.
• Historically, Current Assets has averaged $360.8 million across 3 years, with a median of $330.3 million in 2025.
• Annual changes were most pronounced in 2024 — Current Assets soared 296.87% — and 2025, when it plunged 45.02%.
• Telix Pharmaceuticals' Current Assets stood at $151.4 million in 2023, then jumped by 296.87% to $600.7 million in 2024, then slumped by 45.02% to $330.3 million in 2025.
• Business Quant data shows TLX's Current Assets at $330.3 million in Q4 2025, $600.7 million in Q4 2024, and $151.4 million in Q4 2023.